CPRK, NXPC, QMCI, MGRN, BSRC
QMNM, EPTI, GRMU, PLTG, CYXN, AROX, TRBN
Our Stocks to Watch today include Copper King Mining Corp. (OTC: CPRK), NeXplore Corp. (OTC: NXPC), QuoteMedia Inc. (OTCBB: QMCI), Monogram Energy Inc. (OTC: MGRN), BioSolar Inc. (OTCBB: BSRC), Quest Minerals & Mining Corp. (OTCBB: QMNM), EnsurApet Inc. (OTCBB: EPTI), GREM USA (OTCBB: GRMU), Platina Energy Group Inc. (OTCBB: PLTG), China Yongxin Pharmaceuticals Inc. (OTCBB: CYXN), Alderox Inc. (OTCBB: AROX) and Trubion Pharmaceuticals Inc. (NASDAQ: TRBN).
COPPER KING MINING (OTC: CPRK)
"Up 18.06% in morning trading"
Copper King Mining Corporation currently owns approximately 1200 acres in the Drum Mountains of Utah, which are patent deeded mining claims which contain gold, silver and copper. The company recently added to its holdings by filing six more claims on land which was inside their holdings, but not patent deeded. Contiguous to that acreage is approximately 1100 acres of claims filed by Western Utah Copper Company. As the companies explored the concept of a joint venture on the Drum Mountain properties, it was decided that a very viable consideration was to join the total assets of both companies.
June 19 -
Copper King Mining Corporation Announces Receipt of Beaver County Inducement Resolution for Long-Term Bond Financing
Copper King Mining Corporation (OTC: CPRK), an ore mining, processing, and exploration company located in Milford, Southern Utah, announced that it has obtained, through its wholly owned subsidiary, Western Utah Copper Company (WUCC), an inducement resolution from Beaver County, Utah, to issue taxable Industrial Revenue Bonds totaling $100,000,000.
The Beaver County inducement states in part:
The Bonds issued by the County under the provisions of this Resolution shall not constitute nor give rise to a general obligation, debt or liability of the County, or a charge against its general credit or taxing powers. Nothing contained in this Resolution or in any other instrument shall be considered as indebtedness of the County or as obligating the County to any pecuniary liability or a charge against or upon the general credit of the County or against its taxing powers. Such limitations shall be plainly stated and printed upon the face of said Bonds.
The bonds will be purchased by OCS Capital Group LLC’s investment banking house. Copper King received a firm letter of commitment in advance for the purchase of these bonds. The commitment states in part:
The foundation is a qualified sophisticated institutional investor as defined by SEC rule 144(a) and is not relying on, or intending to remarket the bonds.
The foundation will purchase the entire issue of the taxable Bonds in an aggregate principal amount not to exceed $100,000,000.
OCS, an OCS American Limited Liability Company, is an international bond-law consulting firm with offices in Pennsylvania, Washington DC, and Albuquerque NM. It is also a consultant on government relations and government affairs. It provides technical and professional services to local, municipal, state and federal government agencies in the United States and South America.
OCS past projects have ranged from $25 Million, up to $8.3 Billion and vary from mining to commercial developments in cities and towns. Additional information will be released as approved by the lender.
NEXPLORE CORPORATION (OTC: NXPC)
NeXplore Technologies is developing a Web 2.0 search engine and an assortment of social networking portals and tools that will enable users to personalize their Web experience and tailor it to their unique needs, interests, and online pursuits. The Company’s social computing platform, MyCircle.com, offers an enhanced, user-friendly graphical interface search engine, combined with innovative backend technology, which enables users to improve the way they connect with information and other people on the Worldwide Web. MyCircle’s Web 2.0 interface provides users with an online tool for sharing their Blogs, Voice-Over IP, photos and documents, podcasts and videocasts, classified advertising, instant messages, SMS text messages, Chat and personal profiles.
June 20 - NeXplore Featured on WallSt.net's News Magazine on Sunday
WallSt.net’s News Magazine, a half-hour television program that airs on Sundays at 5:30 p.m. EDT on the Fox Business Network, features compelling interviews with public company CEOs, informative trading strategies from investment professionals, and the latest headlines from public companies from around the world.
Among the companies scheduled to be profiled this weekend are NeXplore Corp. (OTC: NXPC), a company that improves the online experience by providing Web tools and destinations that empower people to drive and define a World Wide Web perfectly suited for their unique needs, interests and online pursuits.
INC. (OTCBB: QMCI)
Inc. is a leading software developer
and provider of real-time streaming financial market
information, decision-support, news and research solutions
to brokerage, financial services companies, business
and media corporations. Among its many leading-edge
products lines, the Company offers data feeds, news,
dynamic market content solutions, interactive stock
research tools, financial applications and real-time
wireless applications. QuoteMedia provides data and
services for companies such as the NASDAQ, the OTCBB,
Dow Jones & Company, Forbes.com, Scotia Capital,
Business Wire, Southwest Securities, Regal Securities,
FBR Direct, Broadridge Financial Solutions, Inc.,
AIM Trimark, Zacks Investment Research, ChoiceTrade,
QTrade, Schaeffer's Investment Research, Automated
Financial Systems, WallStreet*E, and others. For more
information, visit www.quotemedia.com.
June 18 - Captivate Broadens Business Programming with QuoteMedia
QuoteMedia, Inc. (OTCBB: QMCI) announced an agreement to provide market data feed services to Captivate Network, a subsidiary of Gannett Co., Inc. (NYSE: GCI).
Captivate Network, the digital at-work news and entertainment network, has selected QuoteMedia to provide financial quotes and market data to more than 2.6 million business professionals via nearly 8,400 wireless, digital screens located in the elevators of premier office towers in 24 of North America's largest markets. QuoteMedia joins a list of major media partners to provide programming for the network, including CNN, USA Today, CNET and Forbes.
“With our core market of business professionals across North America, it is vital that we continue to execute our strategy of providing 'Best in Class' programming to our viewers. QuoteMedia provides Captivate with timely, reliable and key information about business and financial markets, which compliments our business coverage,” said Mike DiFranza, president and general manager for Captivate. “We were impressed with the quality of QuoteMedia’s market coverage, their technological strength and particularly the level of support they provide. QuoteMedia has worked with us to ensure we are providing our viewers with the most up to date financial information possible.”
“We are very pleased with this exciting opportunity to provide financial information and market data to nearly 3 Million viewers through this new digital channel,” said Dave Shworan, CEO of QuoteMedia, Ltd. “Captivate is a recognized leader in the business focused digital marketplace, with a well deserved reputation for the quality and diversity of their programming. Their decision to use our data services is a wonderful endorsement of our product, and it provides a great opportunity to connect with their highly targeted audience of business professionals while exposing QuoteMedia’s brand to millions of viewers.”
ABOUT CAPTIVATE NETWORK
Captivate Network (www.captivate.com), is the North American news and entertainment network that delivers quality programming and advertising to a highly desirable and targeted audience during the workday, when they are making business and personal buying decisions. Captivate is one of the most effective advertising vehicles available, earning a high 48% average total ad recall, according to Millward Brown studies(a). Captivate’s network is seen in a distraction-free viewing environment, on wireless flat-panel television screens in the elevators of premier office towers across North America. Currently, Captivate is seen on nearly 8,400 screens, delivering more than 55.4 million impressions per month. Established in 1997 and headquartered in Massachusetts with offices throughout North America, Captivate Network is a Gannett company.
MONOGRAM ENERGY INCORPORATED (OTC: MGRN)
"Up 12.50% in morning trading"
Monogram Energy, Inc. is an independent energy company engaged in the acquisition, development, and exploitation of oil and gas properties. The company specializes in acquiring oil & gas leases with proven reserves that have the potential for increased production.
June 16 - Monogram Energy, Inc. in Negotiations for Well in Montana Williston Basin
Monogram Energy, Inc. (OTC: MGRN), an independent energy company engaged in the acquisition, development, and exploitation of oil and gas properties, announced that the Company is in negotiations to work over and complete a well located in the Williston Basin in Montana. A registered professional geologist examined the well and reported the following:
"Based on acceptance of the reservoir model and historical characteristics of the producing formations in the Williston Basin, the well is a viable prospect contingent on plugging back the well bore to above the oil water contact and exploiting existing fracture porosity as a hydrocarbon delivery system. Several features of the well make such a course of action particularly attractive, not least of which is the fact that the well is already drilled and cased."
Mr. Billy King, Chief Executive Officer of Monogram Energy, Inc. stated, "Given this and other studies, it is the generally accepted position that this well has the possibility of producing some 600 barrels per day. Consequently, we are moving forward as quickly as possible."
Mr. King became interested in the production of oil & gas during his ten years of employment as an attorney for the Halliburton Company, and with his representation of independent oil companies during his years as a private practitioner. Monogram Energy's goal is to maintain a high risk/reward profile, thereby enabling them to return the most value to its shareholders.
BIOSOLAR INCORPORATED (OTC: BSRC)
BioSolar, Inc. engages in the research and development of bioplastic materials from renewable plant sources for use in photovoltaic solar cells. The company develops bio-based plastics components that meet the thermal and durability requirements of solar cell manufacturing processes for conventional crystalline cell designs, as well as thin film photovoltaic devices in an effort to capitalize on cost advantages to current petroleum based solar cell components. Its bioplastic materials can be also used directly in conventional manufacturing systems, such as injection molding and thin-film roll-to-roll, to create superstrate layer, substrate layer, and backsheet, as well as module and panel components. The company was founded in April 2006. It was formerly known as BioSolar Labs, Inc. and changed its name to BioSolar, Inc. in June 2006. BioSolar, Inc. is headquartered in Santa Clarita, California.
June 16 - BioSolar Set for Full Scale Production of Flagship BioBacksheet with Selection of Rowland Technologies
BioSolar, Inc. (OTCBB: BSRC), developer of a breakthrough technology to produce bio-based materials from renewable plant sources that reduce the cost of photovoltaic solar cells, today announced it has selected Connecticut-based Rowland Technologies, Inc., a leading manufacturer of plastic film and sheet, as its manufacturing partner for full-scale production of the company's flagship BioBacksheet™ solar cell component.
"After an exhaustive selection process it was evident that Rowland Technologies was uniquely positioned to meet our requirements," said Dr. David Lee, BioSolar's CEO. "Specifically, Rowland Technologies' expertise in sophisticated extrusion manufacturing and their highly-regarded custom manufacturing capabilities, coupled with our shared commitment to being both environmentally aware and yet economically feasible, allowed us to achieve the common goal of delivering the highest quality product to our customers."
Dr. Stan Levy, BioSolar's chief technology officer, who spearheaded the selection process, noted that "Rowland Technologies' high-performance products are recognized throughout the industry for their consistency and reliability. In addition to their own film products which include RowTec(R) polycarbonate film, SolaTuf(R) impact modified acrylic film, ROWLAR(TM) photovoltaic glazing film, and Rowlux(R) illusion film, Rowland Technologies makes available their highly experienced Research & Development team for custom extrusion projects. This team, working with their state of the art equipment, makes Rowland a prudent choice for the manufacture of BioSolar's BioBacksheet product."
Commenting further on the company's growth from an early development stage company to a manufacturing company, Dr. Lee said, "I want to emphasize the challenging and time consuming nature of transitioning into manufacturing. We are implementing our internal quality control and measurement standards, developing the logistics for shipping and handling product and building up our marketing and sales infrastructure. This has been an exciting and sometimes exhausting endeavor, but with quality partners like Rowland Technologies, I firmly believe we are on track to achieve commercial success."
In a related development that emphasizes the high level of industry interest in the groundbreaking nature of the BioBacksheet product, the company also notes that Dr. Levy is to deliver a key oral presentation at the SPIE Symposium on Solar Applications and Energy in August of this year. This forum will allow Dr. Levy to discuss in detail the various scientific breakthroughs underlying the company's BioBacksheet™ product.
SPIE Optics+Photonics is the largest optical sciences and technology meeting in North America. The Solar Energy + Applications track of the conference is dedicated to finding ways to move toward secure, affordable, and environmentally sustainable energy to meet the world's accelerating energy needs.
ABOUT ROWLAND TECHNOLOGIES, INC.
Rowland Technologies, Inc., located in Wallingford, CT, is a specialty extruder of high quality film and sheet. Rowland provides leading-edge solutions for a wide range of applications worldwide, including the photovoltaic and solar cell industry. As a premier supplier and contract manufacturer, Rowlands' products deliver the clarity, consistency and reliability demanded by today's exacting standards. To learn more about Rowland Technologies, visit the company's Web site at www.rowtec.com.
QUEST MINERALS & MINING CORPORATION (OTCBB: QMNM)
"Up 84.91% in morning trading"
Quest Minerals & Mining Corp. engages in the acquisition and operation of energy and mineral related properties in the southeastern part of the United States. It owns leasehold interests in various coal properties in eastern Kentucky. The company was founded in 2003 and is based in Paterson, New Jersey.
June 20 -
Quest Minerals & Mining Announces Rapidly Approaching Production Phase
Quest Minerals & Mining Corp. (OTCBB: QMNM) (Frankfurt: QMNB.F), a Kentucky based operator of energy and mineral related properties, announced that it is diligently working to conclude their final stages of rehabilitation so that they can move into full production. The company is currently preparing to mine its Pond Creek location, held under its wholly owned subsidiary, Gwenco, Inc.
Eugene J. Chiaramonte, Jr., President of Quest Minerals and Mining Corp., stated, "I have spent many hours underground to ensure that we are mining as soon as possible. Despite some minor encounters related to equipment delays, our long awaited production phase is imminent. Pending any unaccountable obstacles, we expect to be ready for production within a week to two weeks. The company is eager to launch its $8 million contract fulfillment with Logan & Kanawha Co., LLC. We will provide continual updates as production incurs."
ENSURAPET INCORPORATED (OTCBB: EPTI)
"Up 71.43% in morning trading"
Ensurapet, Inc., a development stage company, provides pet health information services to pet owners, veterinarians, animal healthcare professionals, and pet service providers primarily in the United States and the United Kingdom. Its health information services include life and health insurance for pets, horses, and other companion animals through public online portals. The company offers online animal healthcare information, decision-support applications, communications services, and insurance applications that enables pet owners to obtain information on diseases or conditions, analyze symptoms, locate veterinarians, store their pet's healthcare information, receive periodic e-newsletter, and participate in online communities with pet owners and veterinarians. Its services also enable users to access clinical reference sources, learn about treatment options, and communicate with peers; and enables pet owners, veterinarians, insurance agents, and employer and employer/group organizations to provide employees and members with access to pet life and health insurance plans for companion animals. Its public portals include ensurapet.com; vetpetmd.com; purrfectpetclub.com; spotthepet.com; purrfectpetinsurance.com; and purrfecthorseinsurance.com. The company, formerly known as Vsurance, Inc., was founded in 2005 and is based in Santa Ana, California.
June 19 -
EnsurApet Announces 'Protect 4' Pet Health Insurance Plans
EnsurApet Becomes 1 of Only 3 Pet Health Insurance Providers Across the Entire Pet Health Insurance Industry to Offer Coverage for Medical and Preventive Treatments for Everyday Common Dog and Cat Illnesses
EnsurApet, Inc. (OTCBB: EPTI), a provider of pet health insurance, announced today that the Company’s “Protect 4” Pet Health Insurance Plans offer dog and cat owners an insurance plan which provides coverage for preventive and medical treatments of common canine and feline illnesses.
The EnsurApet “Protect 4” plan provides the most coverage of any pet insurance plan in the marketplace today. The coverage includes vaccinations, dental cleaning, kitten boosters, puppy boosters, feline infectious peritonitis and feline leukemia as well as vaccines. The “Protect 4” Insurance Plan is a complete healthcare plan for preventive and major medical care.
“With over 141 Million dogs and cats in the United States alone and over 62% of all US households owning a pet there is clearly a demand for our ‘Protect 4’ Insurance Plans. EnsurApet is one of only three pet health insurance providers industry-wide to offer such coverage. This allows EnsurApet to rapidly expand its market share and to substantially increase the company’s number of policy holders through joint venture projects with major pet retails across the country looking for ways to provide additional products to their customers,” stated Russell Smith, CEO.
The Company’s “Protect 4” policy covers the most common dog and cat illnesses including:
* Urinary Tract Infections. Commonly treated with Antibiotics.
* Upper Respiratory Infection (known as URI), which is very similar to the common cold in humans.
* Feline Distemper caused by a virus, however curable with the vaccine, Feline Distemper (FVRCVP).
* Chronic Kidney Failure. Common treatments include an IV drip for dehydration and kidney dialysis.
* Diabetes in cats. There are a number of possible treatments including cat insulin shots.
* Parvovirus in dogs, categorized as a viral disease.
* Rabies virus. Commonly prevented by vaccination.
* Distemper, caused by a virus referred to as CDV (canine distemper virus).
GREM USA (OTCBB: GRMU)
"Up 40.00% in morning trading"
GREM USA, Inc., a development stage company, engages in the design and manufacture of custom handmade and mass-produced electronic guitars, amplifiers, and accessories. The company was formerly known as Global Business Markets, Inc. and changed its name to GREM USA, Inc. in December, 2004.The company was incorporated in 1999 and is based in Fort Wayne, Indiana.
June 17 -
GREM USA Releases Additional Information Regarding Ongoing Merger Discussions
GREM USA (OTCBB: GRMU) ("GREM," "the Company"), an emerging leader in the design and manufacturing of custom hand-crafted and electric guitars, released additional information regarding the Company's previously-announced introductory merger talks.
The Company is appreciative of the overwhelming show of support it has received, from emails and telephone calls, following the disclosure that GREM was commencing introductory merger talks with a top-tier guitar manufacturer. Due to the volume of communication we received, the Company wishes to address the more frequent inquiries from shareholders so that others who were unable to contact us may also understand the developments more clearly.
The Company has received numerous inquiries as to the identity of the proposed merger candidate, and has become aware that some shareholders have even telephoned the offices of manufacturers seeking comment on the Company press release. While the Company acknowledges the importance of independent research, management wishes to advise shareholders that under existing non-disclosure agreements (NDA), the potential merger partner would be unable to legally confirm the existence of any talks with GREM altogether. The Company is working towards creating an agreement whereby GREM may publicly disclose this information in the future.
Some shareholders have also asked the Company to clarify its statement that a successful merger would require a share consolidation. Investors should be apprised that such a consolidation would only occur after a definitive agreement has been signed by both parties, and would occur with a simultaneous change of control of the Company. Because of the very large difference in market capitalization between the two companies, shareholders would benefit from what would likely be a favorable arbitrage. In a share consolidation, the value of one's holdings should not change, and in respect to a completed merger transaction, it is likely the market would reflect a capitalization more appropriate for the income, assets, and business prospects of the merger candidate. The Company has no current plans to undertake a share consolidation outside of one that would be required to complete a merger transaction and complete change of control.
Individuals who have contacted third-party instrument manufacturers regarding the Company's merger plans are formally asked to cease this activity. Disrupting the business of third-party manufacturers wholly unrelated to GREM USA does not benefit the Company or its shareholders. Although by no means a desired course of action, any individuals attempting to interfere with the Company's merger discussions will be assumed to intend financial harm on the Company and its shareholders, and will face legal action. The Company is working within a process to provide additional transparency regarding merger developments, and shareholders are kindly asked to remain patient until further information is able to be announced.
PLATINA ENERGY GROUP (OTCBB: PLTG)
"Up 25.81% in morning trading"
Platina Energy Group, Inc., an exploration stage company, engages in the exploration and development of oil and gas properties. It owns interests in the Hall and Kirkpatrick leases in the Palo Duro Basin located in Swisher and Hale County; and oil and gas leases located in Young County in Texas. The company also owns interests in various oil and gas leases in the Devonian Black Shale formation located in the Appalachian Basin of east Tennessee. In addition, Platina Energy Group owns certain rights in Thermal Pulse Unit (TPU), a proprietary enhanced oil recovery technology that utilizes a hydraulic gas compressor to enhance the production of mature oil fields and stripper wells. The TPU creates 350F+ heat and 1,500+psi pressures for utilization in well cleanup, stimulation, and production. The company was incorporated in 1988 as Windom, Inc. and after undergoing various business changes, the company's name was changed to Platina Energy Group, Inc. in 2005. Platina Energy Group is headquartered in Cheyenne, Wyoming.
June 19 -
Platina Energy Group Connects More Wells to Pipeline in Kentucky
Platina Energy Group, Inc. (OTCBB: PLTG) (Frankfurt: O5Y.F) reports as of the close of business on Thursday, June 19, 2008, more gas wells have been connected to the pipeline for purchase by a major supplier.
Blair Merriam, President of Platina stated, "Combined production should range in the 750-1000 mcf/day. At current gas pricing, annualized revenue run-rate should rise to exceed $4,000,000+ from the new connections by the end of June. We are only part way done with our present developmental program in Kentucky, but expect to enjoy cash flows beginning in July and a healthy revenue stream from these wells for years to come."
According to Joel Patton, field management for Platina, "We've been working at top speed to get these wells on line in Kentucky as in addition to our Tennessee field. We're very excited about the revenues that these wells will deliver as both areas have long histories of consistent production."
CHINA YONGXIN PHARMACEUTICALS (OTCBB: CYXN)
"Up 17.19% in morning trading"
China Yongxin Pharmaceuticals, Inc. engages in the wholesale distribution of pharmaceutical products, medical products and equipment, herbal and nutritional supplements, and cosmetics to hospitals, clinics, and retail pharmacies primarily in the People's Republic of China. It also operates drugstores that offer 8,000 different types of products, including its proprietary brand of ginseng-based products, as well as an assortment of other merchandise comprising traditional Chinese medicines, health and natural products, skin care products, and cosmetics. In addition, the company involves in the cultivation, processing, manufacture, and distribution of ginseng electuary, pellets, and liquid extracts that are distributed by wholesalers and in retail drugstores. It markets and distributes its ginseng and ginseng by-products under the proprietary Gaoliyuan i(degree)Zinuo, Longlife, and Yongxintang brand names to various pharmaceutical, health supplement, and cosmetic manufacturers and distributors in mainland China, the Southeast Asia, Europe, and the United States. The company was founded in 1993. It was formerly known as Nutradyne Group, Inc. and changed its name to China Yongxin Pharmaceuticals, Inc. in May 2008. The company is headquartered in City of Industry, California.
June 18 -
China Yongxin Pharmaceuticals Updates Investors on Performance and Growth Prospects in Special Letter to Shareholders
CEO's Letter Notes 23% Growth in Revenues and 150% Gain in EPS in 2007, Expects Continued Double-Digit Growth Through Drug Retailing Business
China Yongxin Pharmaceuticals Inc. (OTCBB: CYXN), a leading distributor and retailer of pharmaceuticals in Northeastern China, released a Special Letter to Shareholders from Yongxin Liu, the Company’s Chairman and CEO. The text of the letter follows:
Dear Fellow Shareholder,
I am writing you today, for the first time, as Chairman and Chief Executive Officer of a newly named public company. As an enterprise we are 15 years old. But our current corporate identity was established on May 20, 2008, when we changed our name and stock symbol to China Yongxin Pharmaceuticals Inc. and our stock symbol to CYXN (traded on the OTC Bulletin Board). These steps followed other steps, including a reverse merger that will enable us to access the U.S. equity markets for the first time in our history.
These changes alone would be sufficient reason for me to give you an update on our financial performance and market opportunities, so that you can get a clear picture of our past and relate it to our present and future as China Yongxin Pharmaceuticals. But this would be an exciting time for us, and well worth writing about, in any event.
Company Boasts Regional Strength
As you may already know, Yongxin is a leading drug distributor and retailer in China’s Jilin Province, a region with a population of over 27 million. Despite operating in a highly fragmented market (in 2007 there were 956 pharmaceutical wholesalers and 69 chain drugstore operators in Northeastern China alone) we stood out as one of the strongest regional players in China’s vast and growing pharmaceutical retailing industry.
On the wholesale side, we have become the leader in medical logistics and distribution in the Jilin Province. Our product and service lines cover Chinese patent medicine, decoction pieces, chemical medicine preparation, health products, food, cosmetics and medical equipment. Its offerings number nearly 10,000 in all. Our customers include major hospitals, clinics, community clinics and retail drugstores. In addition, we have built strategic partnerships with many large-scale medical enterprises that we expect to leverage in the near-future as part of our growth strategy. Current strategic partners include Johnson & Johnson in China, Wyeth in China, Pfizer in China, Bayer in China and Novo Nordisk in China.
In retailing, our most promising growth area, our customer member count had reached about 300,000 at the end of 2007, with 87 chain stores in operation. During 2008, we expect to open 20 new drugstores. By the end of June 2008, we had already opened six of those 20 drugstores. The successful execution of this expansion plan would rank our retail chain store as the largest not only in the Jilin Province but in all of Northeast China. We expect our retail growth to be enhanced significantly in the near future by our franchise to operate under a globally recognized pharmaceutical brand in Jilin Province.
Finally, we are entering the potentially lucrative business of manufacturing ginseng-based products in a vertically integrated operation, from cultivation to final sales.
Sales, Margins and Earnings Soar in 2007 to New Record Highs for Company
Our 2007 financial results clearly demonstrate that we are already a fast-growing company, mainly on the strength of our wholesaling – the oldest and most fully developed part of our business. From 2006 to 2007, our revenues increased 23%, from $39.0 million to $47.9 million. Economies of scale and other efficiencies pushed our gross margins sharply higher, from 8.3% to 16.7%, providing us with a 146% year-over-year gain in gross profits. Operating profit was up more than 14 times, from $283,000 to $4.12 million. Net income rose by 154%, with earnings per fully diluted share up from $0.08 to $0.20.
How will we keep such momentum going? The answer lies in China’s overall growth and, in particular, the growth of drug sales to its increasingly affluent middle-class, the update of China’s social security system and the country’s aging population. A recent report by the research firm Renaissance Capital (focused on our largest publicly-traded competitor, China Nepstar Chain Drugstore) predicts that retail drug sales in China will grow by 20% annually to $30 billion in 2011. This is a market where even the largest players claim only small fractions of the potential demand. And if China Yongxin Pharmaceuticals is not among the largest nationwide firms, at least not yet, it has an impressive springboard for national expansion in its strong regional base – its leadership in Jilin Province – as well as in its supply-chain integration and experience.
In the coming weeks, we expect to be delivering more news about our recent performance and accelerating growth prospects, including the progress of our expansion in Jilin Province and beyond. For now, there are two key points to remember. The first is that China Yongxin Pharmaceuticals has more than proven itself in its home market and is preparing to take its winning formula to a wider arena across China in an effort to accelerate its strong double-digit growth rate. The second is to remember that every decision by this Company’s management team, particularly as majority shareholders, will be made by one primary factor: to achieve our fiduciary duty to enhance your investment in China Yongxin Pharmaceuticals.
Chairman and Chief Executive Officer
To be added to China Yongxin Pharmaceuticals’ investor lists, contact Haris Tajyar at
or at 818-382-9702.
ALDEROX INCORPORATED (OTCBB: AROX)
"Up 9.68% in morning trading"
Alderox, Inc. engages in production and sale of release agents principally for the paving, mining, and asphalt industries. The company offers Alderox line of products, including ASA 12, an ore and asphalt release agent; DCR, a drag chain and conveyer belt lubricant; PaverBlend, a asphalt related product used to keep paving equipment free from debris; KR-7, a concrete release agent; and ASA Cleaners. Its release agents are applied to containers, mixers, truck beds, truck undercarrages, skips, loaders, chutes, buckets, conveyers, and forms and act as a barrier to mitigate adhesion of ore, asphalt, concrete, or other material to the relevant surfaces. The company sells its products in the United States, Canada, Mexico, and Puerto Rico. Alderox was formerly known as Reclamation Consulting and Applications, Inc. The company was founded in 1976 and is based in San Clemente, California.
June 18 -
Alderox, Inc. & 3M Canada Company Sign Exclusive Supply Contract
Alderox, Inc. (OTCBB: AROX), a world leader in productivity enhancing, environmentally friendly anti-stick release agents and lubricants to the mining sector, announced that it has entered into a long term supply contract with 3M Canada Company. Under the terms of the Agreement, 3M Canada has exclusive rights to the Company's patented Alderox products for the Canadian mining industry, including the oil sands.
Gordon Davies, President of the Company stated, "The supply agreement with 3M Canada is a significant and very positive event for Alderox, Inc. Not only will the relationship with 3M Canada speed up the development of the Canadian mining and oil sands markets, the fact that 3M Canada has put their name and resources behind our Alderox product confirms that it is a superior solution to the carryback and ore build-up issues in the mining sector." Mr. Davies concluded, "We are pleased to be involved with 3M Canada and looking forward to a long and mutually successful relationship with them."
TRUBION PHARMACEUTICALS INCORPORATED (NASDAQ: TRBN)
"Up 4.17% in morning trading"
Trubion Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing protein therapeutic product candidates for the treatment of autoimmune and inflammatory diseases, and cancer. Its lead product candidate TRU-015, which has completed a Phase IIb clinical trial is designed for the treatment of rheumatoid arthritis, non-Hodgkin's lymphoma (NHL), and systemic lupus erythematosus. The company also offers TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia, and NHL. It has collaboration agreement with Wyeth for the development and commercialization of TRU-015 and other therapeutics directed to CD20, an antigen validated clinical target present on B cells; and SMIP product candidates directed to a small number of targets other than CD20. The company was founded in 1999 and is headquartered in Seattle, Washington.
June 19 -
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
Trubion Pharmaceuticals Inc. (NASDAQ: TRBN) announced that Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE - News), has exercised its option under the terms of its collaboration agreement with Trubion to extend the research period for an additional one-year period through Dec. 22, 2009. Under the terms of the research period extension, Wyeth's obligations to Trubion include collaboration research funding commitments of approximately $3.2 million in exchange for committed research services through Dec. 22, 2009.
"We are pleased that Wyeth has extended the research period of our collaboration," said Peter Thompson, M.D., FACP, president, CEO and chairman of Trubion. "Wyeth's ongoing commitment to the collaboration underscores the potential of our technology, and we look forward to continuing our efforts with Wyeth as we pursue the development of additional first-in-class and best-in-class compounds."
In December 2005, Trubion entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of TRU-015 and other CD20-directed therapeutics. The agreement also includes the development and worldwide commercialization of certain other product candidates directed to a small number of targets other than CD20 that have been established pursuant to the agreement. Unless earlier terminated, the agreement will remain in effect on a product-by-product basis and on a country-by-country basis until the later of the date that any such product shall no longer be covered by a valid claim of a U.S. or foreign patent or application and, generally, 10 years after the first commercial sale of any product licensed under the agreement. Wyeth may terminate the agreement without cause at any time upon 90 days' prior written notice.
Trubion retains the right to develop and commercialize, on its own or with others, product candidates directed to all targets not included within the agreement, including CD37.